Triple combination of Sotorasib, GDC-0941 with SHP2 inhibitor SHP099 exhibits a more pronounced anti-tumor effect than Sotorasib dual combination with either GDC-0941 or SHP099.485 Moreover, a histologic transformation from adenocarcinoma to squamous cell carcinoma was discovered in two out of ten patients (nine NSCLC patients and one colorectal tumor patient) who developed acquired resistance after the treatment with KRASG12C inhibitor [Fig. 8c]. The gene discussed is PTPN11; the disease is neoplasm.